Abstract
A population attributable fraction (PAF) represents the relative change in disease prevalence that one might expect if a particular exposure was absent from the population. Often, one might be interested in what percentage of this effect acts through particular pathways. For instance, the effect of excessive alcohol intake on stroke risk may be mediated by blood pressure, body mass index and several other intermediate risk factors. In this situation, attributable fractions for each mediating pathway of interest can be defined as the relative change in disease prevalence from disabling the effect of the exposure through that mediating pathway.
This quantity is related to, but distinct from the recently proposed metrics of direct and indirect PAF by Sjölander. In particular, while differing pathway-specific PAF will each usually be less than total PAF, they may sum over differing mediating pathways to more than total PAF, whereas direct and indirect PAF must sum to total PAF. Here, we present definitions, identifiability conditions and estimation approaches for pathway-specific attributable fractions. We illustrate results, and comparisons to indirect PAF using INTERSTROKE, a case-control study designed to quantify disease burden attributable to a number of known causal risk factors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. O'Connell and Dr. Ferguson are funded under the HRB grant EIA-2017-017
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
HRB Ireland
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
R-code for running the analyses in this manuscript can be obtained by contacting the authors
